## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Cannabidiol (Epidiolex)

#### Notes:

+ <u>AEDs for Lennox Gastaut</u>: felbamate, valproate, topiramate, lamotrigine, rufinamide, clobazam, clonazepam, zonisamide; <u>AEDs for Dravet Syndrome</u>: valproate, clobazam, levetiracetam, topiramate, zonisamide, clonazepam, ethosuximide, stiripentol; <u>AEDs for Tuberous Sclerosis Complex</u>: valproate, vigabatrin, levetiracetam, carbamazepine, clobazam, lamotrigine, oxcarbazepine, topiramate # Significant hepatic impairment: liver function tests (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal

Initiation (new start) criteria and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Nonformulary cannabidiol (Epidiolex) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurologist
- Patient is 1 year old or older
- Prescribed for seizures associated with Dravet Syndrome OR Lennox-Gastaut syndrome OR Tuberous Sclerosis Complex
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to at least 2 other antiepileptic medications (AEDs) that are appropriate for diagnosis<sup>+</sup>
- No significant hepatic impairment<sup>#</sup>
- Patient is not using cannabis or other cannabis derivatives

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>. Non-formulary **cannabidiol** (**Epidiolex**) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Patient is 1 year old or older
- Prescribed for seizures associated with Dravet Syndrome OR Lennox-Gastaut syndrome OR Tuberous Sclerosis Complex
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to at least 2 other antiepileptic medications that are appropriate for diagnosis<sup>+</sup>
- Patient is not using cannabis or other cannabis derivatives

kp.org

Revised: 03/10/22 Effective: 05/05/22 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE


## Cannabidiol (Epidiolex)

<u>Continued use criteria for patients stable on the medication:</u> Non-formulary cannabidiol (Epidiolex) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by Neurologist
- Sustained improvement in seizure control (frequency and/or severity) since starting Epidiolex as assessed and documented by neurologist
- No significant hepatic impairment<sup>#</sup>
- Patient is not using cannabis or other cannabis derivatives
- Office visit or telephone visit with neurologist within the past 12 months

kp.org

Revised: 03/10/22 Effective: 05/05/22





All plans offered and underwritten by